FuRong Investment
复容投资
FuRong Investment (复容投资) is a Chinese venture capital firm that appears in elsewhere's corpus primarily as a co-investor in biotech deals, typically alongside larger leads. It followed GaoRong Capital into Yinjia Biotech's Pre-A round in July 2021 , and re-upped in Biointron's nearly RMB 500 million Series B in August 2022 alongside GaoRong, Cornerstone Capital, and others . The firm also backed Yinjia Biotech again in its near-RMB 100 million Series A in January 2023 . Its pattern suggests a focus on life sciences, particularly antibody discovery and protein platform companies, with a tendency to participate in rounds led by more prominent funds rather than lead itself. elsewheres corpus does not cover its founding, AUM, or team.
AI-generated — may contain errors, please verify.
Coverage
Yinjia Biotech Closes Nearly RMB 100 Million Series A Round to Accelerate Buildout of Upstream Core Protein Ingredient Synthetic Biology Platform
Staying true to our mission as "protein craftsmen."
Robotics, SaaS, and innovative drug sectors close new funding rounds; chips and medical devices unveil major new products | Rongbao · August
Differentiated innovation and global opportunities.
Antibody discovery CRO **Baiying Biotech** closes nearly RMB 500 million Series B round
Specializing in antibody discovery CRO services to accelerate antibody drug development.
Yinjia Biotech Closes Pre-A Round, Advancing Its High-End Protein Platform to New Heights
Build a leading domestic "protein artisan" platform.
